Its biggest would-be competitor is ivonescimab, a medicine being developed in the U.S. by Summit Therapeutics. It delivered positive clinical trial results in China in a phase 3 study in which it went ...

Learn how space-based manufacturing is transforming pharmaceuticals with Varda's innovative approach to drug production in ...

High-ranking OpenAI employees have met with the FDA multiple times in recent weeks to discuss AI and a project called cderGPT ...

Inductive Bio, a technology company democratizing artificial intelligence (AI) models to transform small molecule drug discovery, announced today that it has raised $25M in Series A financing led by ...

A research team from the University of Oklahoma has pioneered a method that could accelerate drug discovery and reduce ...

The medical device industry is growing fast in 2025, but faces supply and trade issues. Major companies are set to report earnings on May 7, stay tuned!

Holy Sexuality contacted Asana, a San Francisco-based tech company, and requested the 50 percent discount Asana offers to nonprofits on its project management software. Asana outright denied that ...

Cardiff Oncology has sufficient funds to operate until early 2027 but will face funding challenges by 2026. Learn why CRDF ...

Discover six hemophilia companies developing new treatments for the genetic bleeding disorder, from gene therapies to RNAi ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC) in combination with ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies.

The Food and Drug Administration on Tuesday posted a warning about generic forms of a popular hair-loss medication often sold by major telehealth companies including Hims, Keeps and Ro ...